Targeted Pharmacological Modulation of Cellular Pathology and Drug Discovery: A Translational Approach to Bridge Laboratory Discoveries with Clinical Practice
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 37
Special Issue Editor
Special Issue Information
Dear Colleagues,
The intersection of pharmacology, cellular pathology, and clinical medicine holds immense potential for transforming modern healthcare. This proposal aims to explore how targeted pharmacological interventions can modulate specific cellular pathologies to improve clinical outcomes in diseases such as cancer, neurodegeneration, and chronic inflammatory conditions. By focusing on cellular mechanism such as apoptosis, necroptosis, autophagy, and mitochondrial dysfunction, we will investigate how novel and repurposed drugs influence pathological cell behavior. Our multidisciplinary approach will combine pharmacokinetics, molecular signaling analysis, and histopathological assessments, alongside clinical trial data, to assess drug efficacy and cellular responses. This translational research will bridge laboratory findings with bedside applications, potentially accelerating the development of personalized treatment protocols. The study will also address clinical discipline challenges, such as drug resistance, variability in patient responses, and the need for biomarkers to guide therapy decisions. By integrating pharmacological insights with cellular pathology and clinical data, this research aims to contribute to the design of targeted, effective, and safer treatment strategies that align with the principles of precision medicine.
Topics covered include, but are not limited to, the following:
- Role of Small Molecule Inhibitors in Modulating Apoptotic Pathways in Cancer Cells
- Pharmacological Modulation of Autophagy in Neurodegenerative Diseases
- Targeting Mitochondrial Dysfunction Using Pharmacological Agents in Metabolic Syndromes
- Modulating Inflammatory Cytokine Signaling through Biologic Drugs in Autoimmune Pathology
- Impact of Epigenetic Drugs on Cellular Pathology in Hematologic Malignancies
- Pharmacological Interventions in Cellular Fibrosis: Translating Mechanistic Pathology into Anti-Fibrotic Therapy
- Targeted Pharmacotherapy for Hypoxia-Induced Cellular Injury in Ischemic Stroke
- Drug-Induced Modulation of Angiogenesis in Tumor Microenvironments: Pathological and Clinical Perspectives
- Cellular Pathology of Diabetic Complications: Therapeutic Targeting of Oxidative Stress and Inflammation
- Modulating Cellular Senescence in Aging Tissues: From Drug Discovery to Clinical Anti-Aging Therapies
- Bridging Preclinical Drug Testing with Clinical Efficacy: Case Studies in Targeted Cancer Therapies
- Use of Patient-Derived Organoids to Evaluate Pharmacological Response in Pathological Tissues
- Targeted Nanomedicine Delivery Systems for Site-Specific Modulation of Pathological Cells
- Pharmacogenomic Approaches to Predict Drug Response Based on Cellular Pathology Profiles
- Clinical Trials of Targeted Therapies Guided by Histopathological and Molecular Biomarkers
- Clinical trials for in-vitro fertilization and drug medicine discovery.
- Molecular docking and potential drug discovery
- Epigenetic Age clock for CD+T cell samples and interaction between age clock signature and targeted drug
Dr. Saurav Mallik
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted pharmacotherapy
- cellular pathology
- translational medicine
- drug mechanism of action
- signal transduction modulation
- precision medicine
- apoptosis and autophagy
- biomarker-guided therapy
- pathophysiology-driven drug design
- clinical applications of molecular targets
- molecular docking
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
